Neuroendocrine Tumors Market

1
Neuroendocrine Tumors (NETs) Market Insights,
Epidemiology and Market Forecast - 2028
2
Neuroendocrine Tumors (NET)
01
Neuroendocrine tumors (NETs) consists of complex
group of tumors that arise from cells called
neuroendocrine cells.
02
They develop predominantly in the digestive or
respiratory tracts, but can occur in many areas
of the body.
03
They develop when the specialized cells undergo
changes causing them to divide uncontrollably and
grow into tumor.
04
Neuroendocrine tumors are classified based on
different criteria as an anatomic site of origin
symptoms malignancy grade and stage.
05
Neuroendocrine tumors is more predominant in
males as compared to females.

• DelveInsight 2019 All rights reserved

3
NET Epidemiology
NET total prevalent population was
approximately 452,900 in 2017 in 7 Major Markets
(7MM). In US, NET prevalent cases were 199,000
in 2017. Among the European countries, Germany
had the highest with 49,600 cases followed by
France, which had a prevalent population of
40,000 in 2017. Whereas, Spain had the lowest
prevalent population of 27,000. In 2017, Japan
had 59,000 NET prevalent cases.
7MM- USA, EU-5(Germany, Spain, Italy, France
and UK), Japan

• DelveInsight 2019 All rights reserved

4
Market Outlook
Neuroendocrine tumors therapeutic market was USD
3,570.0 million in 2017 in seven major markets
(7MM) for the study period (2017-2028).
The approved as well as off-label products
(chemotherapy and cytotoxic agents) and targeted
therapies are being used for the NET treatment.
The United States accounts for the largest
Neuroendocrine tumors market size in comparison
to EU5 (the United Kingdom, Germany, Italy,
France, and Spain) and Japan.
Systemic therapies are the options for treatment
of the distant tumors. Radiolabeled Somatostatin
Analog therapies are generally considered as
targeted therapies.

• DelveInsight 2019 All rights reserved

5
Emerging Therapies
01
Drug- Sulfatinib Company- Hutchison MediPharma
02
Drug- Iobenguane I-131 Company- Progenics
Pharmaceuticals
03
Drug- Axitinib Company- Pfizer
04
Drug- Carfilzomib Company- Amgen

• DelveInsight 2019 All rights reserved

6
Complete Information
For complete information on
Neuroendocrine Tumors Market Insights,
Epidemiology and Market Forecast - 2028 please
click the link below
CLICK HERE
OR
Write Us At 
info_at_delveinsight.com

• DelveInsight 2019 All rights reserved

7
About DelveInsight
2
1
3

• DelveInsight 2019 All rights reserved

8
Service Offerings by DelveInsight

• DelveInsight 2019 All rights reserved

9
Contact Us
info_at_delveinsight.com
91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight

• DelveInsight 2019 All rights reserved

10

• DelveInsight 2019 All rights reserved